Issue Information.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 1, doi. 10.1002/cai2.16
- Publication type:
- Article
Works matching IS 27709183 AND DT 2023 AND VI 2 AND IP 4
Results: 10
1
2
Promoting the application of pediatric radiomics via an integrated medical engineering approach.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 302, doi. 10.1002/cai2.44
- By:
- Publication type:
- Article
3
Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin-induced myocardial injury.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 253, doi. 10.1002/cai2.64
- By:
- Publication type:
- Article
4
Severe graft-versus-host disease post allogeneic hematopoietic stemcell transplantation due to loss of HLA heterozygosity in recipient lymphocytes after full graft rejection.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 312, doi. 10.1002/cai2.72
- By:
- Publication type:
- Article
5
The antiferroptotic role of TRIM7: Molecular mechanism and synergistic effect with temozolomide.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 237, doi. 10.1002/cai2.77
- By:
- Publication type:
- Article
6
Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 265, doi. 10.1002/cai2.74
- By:
- Publication type:
- Article
7
Survival nomograms for simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy in patients with resectable colorectal liver metastasis.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 240, doi. 10.1002/cai2.45
- By:
- Publication type:
- Article
8
Progress in research on ultrasound radiomics for predicting the prognosis of breast cancer.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 283, doi. 10.1002/cai2.85
- By:
- Publication type:
- Article
9
Global trends of cancer: The role of diet, lifestyle, and environmental factors.
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 290, doi. 10.1002/cai2.76
- By:
- Publication type:
- Article
10
Correction to "Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed ormetastatic breast cancer".
- Published in:
- Cancer Innovation, 2023, v. 2, n. 4, p. 318, doi. 10.1002/cai2.69
- Publication type:
- Article